Continuous versus intermittent vancomycin infusions in children with severe gram-positive bacterial infections: a randomized controlled trial

preprint OA: closed
View at publisher

Abstract

Objectives This study aimed: (a) to compare the effects of continuous and intermittent infusions of vancomycinon the pharmacodynamics/pharmacokinetics (PK/PD) at a dose of 40 mg.kg -1.d -1 in children; (b) to compare the outcomes and the frequency of the drug-related adverse effects in this population. Methods This single-center randomized controlled trial enrolled children, admitted to the intensive care unit over a period of 36 months (June 1, 2017–June 1, 2020), and required vancomycin therapy. These children were randomly assigned to the CIV and IIV groups. The demographic, indices of PK/PD, outcomes, and drug-related adverse effects were collected and analyzed. Results Of the 92 patients randomized, 90 were included in the analysis and 2 patients dropped out of the trial. The study was conducted on two groups: the IIV group (n = 50) and the CIV group (n = 40) and various parameters were compared. The plateau concentration in the CIV group was higher than the trough concentration in the IIV group (15.22 mg.L -1 vs. 6.25 mg.L -1, P 0.05). None of the two groups showed any significant difference in the clinical prognosis or the drug-induced nephrotoxicity. Conclusions Therefore, CIV can assist in attaining the target concentrations of vancomycin more quickly in critically ill children, without increasing the dosage. Also, the children subjected to CIV demonstrated no difference in clinical efficacy and the rate of drug-related nephrotoxicity.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-05-20T11:00:21.680559+00:00